Stemson Therapeutics Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Stemson Therapeutics's estimated annual revenue is currently $7.8M per year.(i)
  • Stemson Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • Stemson Therapeutics has 50 Employees.(i)
  • Stemson Therapeutics grew their employee count by 32% last year.

Stemson Therapeutics's People

NameTitleEmail/Phone
1
Co-Founder, CEOReveal Email/Phone
2
VP, Product Development & Tissue EngineeringReveal Email/Phone
3
Director Histology and Pathology DepartmentReveal Email/Phone
4
Senior Director BioInformatics and Data SciencesReveal Email/Phone
5
Director Histology & PathologyReveal Email/Phone
6
Project Manager, R&DReveal Email/Phone
7
Senior Manager, Analytical DevelopmentReveal Email/Phone
8
Associate ScientistReveal Email/Phone
9
Senior Analytical AssociateReveal Email/Phone
10
Senior Associate Scientist 1Reveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.4M70-8%$53MN/A
#2
$32.4M167-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.8M1813%N/AN/A
#5
$0.8M5-50%N/AN/A
#6
$0.8M100%N/AN/A
#7
$14M90-12%N/AN/A
#8
$0.4M33610%$236.7MN/A
#9
$4.8M62-74%$160MN/A
#10
$3.7M24-8%N/AN/A
Add Company

What Is Stemson Therapeutics?

At Stemson Therapeutics, we envision a world where anyone battling the emotional trauma or social stigma of hair loss has an opportunity to truly cure their condition and safely restore their natural hair.

keywords:N/A

N/A

Total Funding

50

Number of Employees

$7.8M

Revenue (est)

32%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Stemson Therapeutics News

2022-04-13 - Paul Laikind, PhD, Joins Stemson Therapeutics Board of ...

Stemson Therapeutics is a pre-clinical stage cell therapy company founded in 2018 with a mission to cure hair loss by leveraging the...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$8.4M50-23%N/A
#2
$5.8M50-6%N/A
#3
$7.5M50-12%$269.2M
#4
$3.9M50-35%$39.4M
#5
$3.5M5035%N/A